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Acute methadone toxicity is a major public health concern in Iran. Methadone-intoxicated patients are in a great risk of recurrent
or delayed respiratory arrest despite the prescription of initial doses of naloxone. This study aimed to evaluate the effectiveness of
oral naltrexone in the management of acute methadone overdose in opioid-naive patients and check if it could be a substitute of
continuous infusion of naloxone in maintaining adequate ventilation. In a randomized, double-blind, placebo-controlled study, a
total of 54 opioid-naive patients with acutemethadone toxicity were enrolled.Thepatients received either oral naltrexone or placebo
capsules after awakening by naloxone. All patients underwent close monitoring of respiration. Frequency of respiratory depression
or arrest, need for another dose of naloxone, duration of hospital stay, and adverse outcomes compared between the two groups.
The incidence of respiratory depression was significantly less in those who had received naltrexone. Our results show that single
oral dose of naltrexone is quite efficient in the prevention of recurrent or delayed respiratory arrest in opioid-naive methadone-
intoxicated patients. It can shorten the duration of hospitalization and, as a consequence, decreased the risk of complications.
Further studies are warranted before the generalization of this approach to other patient populations.
1. Introduction
Methadone (MTD) overdose may happen after therapeutic,
recreational, or accidental use. Acute poisoning with this
drug is extremely common in Iran and intentional poisoning
due to the ingestion of MTD syrup has become so popular in
this country within the recent years [1].
Methadone is a synthetic, pure, long-acting opioid-
receptor agonist with a long elimination half-life (almost 48
hours) that may be prolonged up to 56 hours after overdose
or repeated uses [2]. It is available in our country as syrup (a
mixture of R and S forms containing 5mg/mL of MTD) and
5, 20, and 40mg tablets [3]. A review of the registered
MTDoverdoses at Loghman-HakimPoisonCenter in Tehran
revealed an almost 100-fold increase in this toxicitywithin the
recent decade which is probably due to the increased pre-
scription of MTD for treatment of opioid dependence [1, 4].
Respiratory depression ofMTDmaymanifest late and last
for hours because of its long elimination half-life [2]. Deep
respiratory depression, even if short term, can cause profound
hypoxia with complications including hypoxic brain injury
and acute respiratory distress syndrome [5, 6].
Patients who develop significant respiratory depression
may need treatment with naloxone; this is while naloxone has
a short duration of effect in contrast to most opioids. Thus,
the patients need repeated or continuous doses of naloxone
to prevent respiratory depression. If the MTD-intoxicated
2 BioMed Research International
patients do not receive sufficient doses of the antidote, they
may experience respiratory arrest and death [7].
Naltrexone (NLTX) is a competitive long-acting pure
antagonist of opioid receptors and is approved by the Food
and Drug Administration for the treatment of opioid and
alcohol dependence [8]. It seems that it is highly effective in
preventing repeated respiratory depressions and reversing the
effects of 𝜇 opioid agonists. In Iran, NLTX is available in the
form of 50 and 25mg oral capsules [3]. It is readily absorbed
in the gastrointestinal system, and it is said that administra-
tion of 50, 100, and 150mgNLTX capsules can block all opioid
receptors for 24, 48, and 72 hours, respectively [9]. However,
due to its long half-life and high affinity for the 𝜇 opioid
receptors, it may be dangerous in opioid-dependent patients
and can cause severe long-term life-threatening withdrawal
syndrome, heart ischemia, arrhythmias, pulmonary edema,
and even sudden death [6, 7, 10]. Of course, it is not clear
if the cause of naloxone-induced pulmonary edema is the
withdrawal or the opioid itself [6].Theoretically, it seems that
NLTX can prevent respiratory depression and loss of con-
sciousness in opioid-naive patients who refer after acute opi-
oid overdose with long-acting opioids. The aim of this study
was to evaluate the efficacy of single dose of oral NLTX in
managing acute MTD toxicity in such patients.
2. Materials and Methods
A total of 60 MTD-intoxicated opioid-naive patients were
enrolled in this double-blind, placebo-controlled, and ran-
domized clinical trial. Patients who claimed not to be opioid-
dependent and had accidentally or intentionally (suicidal or
recreational) ingested MTD (based on the obtained history)
and had referred to Loghman-HakimHospital Poison Center
between May and August 2012 were included. All had signs
and symptoms of acute opioid toxicity.
Those with active liver disease and increased level of
transaminases (twice the normal range), acute poisoningwith
complications developed before presentation (such as aspira-
tion pneumonia, brain trauma, and acute lung injury), with-
drawal syndrome after taking NLTX, acute withdrawal after
the administration of naloxone on presentation, and early
voluntary discharge were excluded.
History was taken from the patient him-/herself or close
relatives and paramedics in unconscious cases.The diagnosis
was finally confirmed in all patients by bedside urine tests.
The comatose patients confirmed use of methadone after
regaining consciousness. The patients’ data on formulation
of the ingested MTD, time elapsed between the consump-
tion and presentation, and demographic characteristics were
recorded.The patients were examined for signs of toxicity fol-
lowed by pulseoximetry and arterial blood gas (ABG) analy-
sis.
Emergencymanagement of the airway, breathing, and cir-
culation as well as administration of naloxone (if necessary)
were also performed for those with respiratory depression
(respiratory rate below or equal to 10 per minute and/or res-
piratory acidosis (pH< 7.36 and pCO
2
> 44mmHg inABG)).
Both groups were still able to receive the current standard
care without restrictions (naloxone/airway interventions) if
needed.
A bag filled with 60 balls (30 with “A” letter (NLTX group)
and 30 with “B” letter (placebo group) on them) was used. On
admission of each patient, the administrating physician who
was blind to the study drew a ball from the bag. If the letter
on the ball was A, he would give a capsule from the A box
(containing 30 real 50mg NLTX capsules) and if it was B, he
would give capsule from the B box (containing 30 capsules
completely similar to theNLTX capsule filledwith dried pow-
dered milk). None of the treating physicians, patients, and
the trial manager knew which of the boxes contained NLTX.
According to the ball and box, the patients were randomized
into either A or B groups. All patients with loss of con-
sciousness or respiratory depressionwere fully awake and had
normal respiration after administration of naloxone in the
emergency department (ED) and thereforewere able to ingest
the capsules. Altered level of consciousness was categorized
into four groups of deep coma, unresponsiveness to pain,
flaccid paralysis, brainstem reflexes and respirations absence
(grade IV), unresponsiveness to pain (grade III), responds to
pain but not voice (grade II), and lethargy/confusion (grade
I) [11]. They were monitored for LOC, cyanosis, decreased
respiratory rate, decreased ventilation based on ABG results,
and decreased O
2
saturation based on pulse-oximetry results
for at least 48 hours in the hospitalization period. Arterial
blood gas analyses were performed on admission to the ED
and repeated afterwards, if needed.
By the end of the study, the patients who had received
NLTX and those who had received the placebo were com-
pared regarding the prevalence of respiratory depression,
apnea, LOC, and duration of hospital stay. Clinical findings
and data were collected by five fellowships inmedical toxicol-
ogy.Thedatawas analyzed by statistical package for social sci-
ences (SPSS) software version 17 and application of student’s
𝑡-test, Mann-Whitney 𝑈 test, Fisher’s exact test, and Chi-
Square test as indicated. A𝑃 value <0.05 was considered to be
statistically significant. The experiment was conducted with
the understanding and the consent of the human subject. Eth-
ical approval for the study was given by Shahid Beheshti Uni-
versity of Medical Science Ethics Committee (no. 1391-1-113-
9658). The trial was also registered with Iranian Registry of
Clinical Trials (no. IRCT2012062910133N1).
3. Results
Sixty patients older than 14 years of age were entered into our
study. Five were excluded because of early voluntary dis-
charge and one due to withdrawal syndrome after taking
NLTX. Finally, 54 patients (27 in NLTX group and 27 in pla-
cebo group) were studied. The minimum ingested dose of
MTD was 20mg and the maximum dose was 600mg. The
time elapsed between ingestion and hospital presentationwas
from 1 to 24 hours.The data of the patients on presentation at
ED is shown in Table 1.
Prehospital apnea had occurred in 11 patients (20.4%).
Table 2 shows prehospital respiratory status of the patients.
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Table 1: Baseline characteristics of groups NLTX and Placebo.
Characteristics Total NLTX Placebo P value
𝑛 = 27 𝑛 = 27
Age
Mean ± SD — 26 ± 11 31 ± 12 0.03‡
Sex
Male 24 (44.4%) 9 (33.3%) 15 (55.6%) 0.10∗
Female 30 (55.6%) 18 (66.7%) 12 (44.4%)
Mode of toxicity
Suicidal 45 (83.3%) 24 (88.9%) 21 (77.8%) 0.48∗∗
Accidental 9 (16.7%) 3 (11.1%) 6 (22.2%)
Formulation
Tablet 20 (37.0%) 10 (37.0%) 10 (37.0%) >0.99∗
Syrup 34 (63.0%) 17 (63.0%) 17 (63.0%)
Ingested MTD doses
(mg)
Mean ± SD 130 ± 116 153 ± 142 106 ± 75 0.41‡
Time since ingestion
(hrs)
Mean ± SD 6 ± 6 6 ± 5 6 ± 6 0.34‡
†Student’s t-test. ‡Mann-Whitney U test. ∗Chi-Square test. ∗∗Fisher’s exact
test.
Twenty-four (44.4%) patients received a bolus dose of nalox-
one due to respiratory compromise on presentation, 10 (37%)
of whom were in group A and 14 (51.9%) were in placebo
group (𝑃 = 0.27).
A dose of 0.4 to 4mg of naloxone had already been
administrated by the paramedics. Electrocardiography on
presentationwas normal in 40 patients; sinus tachycardia and
QTc corrected prolongation were detected in 8 (14.8%) and 2
(3.7%) patients, respectively.
Table 3 summarizes the patients’ vital signs, respiratory
status, LOC, ABG, and naloxone administration on presen-
tation time at ED.
Table 4 shows the laboratory findings of the patients in
both groups.
Table 5 compares the patients’ outcome between the
groups during hospitalization. Two of our patients in placebo
group underwent tracheal intubation, one due to aspira-
tion pneumonia and one due to noncardiogenic pulmonary
edema. These two patients had also needed more doses of
naloxone (4 and 6mg, resp.) at emergency department (ED)
due to respiratory failure. We had no death in our study.
4. Discussion
Methadone is widely prescribed for treatment of opioid
dependence and pain relief [12, 13]. Recently, accidental or
intentional acute MTD overdose has significantly grown and
become a public health problem in many countries [14, 15].
Ingestion of large or repeated doses may produce sig-
nificant toxicity and lead to fatal respiratory depression.
Thus,most of these patientsmay need respiratorymonitoring
Table 2: The prehospital status of patients.
Characteristics Total NLTX Placebo P value
𝑛 = 27 𝑛 = 27
Pre-hospital Apnea
No apnea 43 (79.6%) 23 (85.2%) 20 (74.1%) 0.38‡
One episode 8 (14.8%) 2 (7.4%) 6 (22.2%)
Two episodes 3 (5.6%) 2 (7.4%) 1 (3.7%)
Bradypnea 27 (50.0%) 11 (40.7%) 16 (59.3%) 0.17∗
Naloxone doses (mg)
Mean ± SD 1.5 ± 0.8 1.5 ± 0.7 1.5 ± 1 0.53‡
Symptoms
Nausea & vomiting 23 (42.6%) 13 (48.1%) 10 (37.0%) 0.41∗
Dizziness 14 (25.9%) 7 (25.9%) 7 (25.9%) >0.99∗
Headache 3 (5.6%) 1 (3.7%) 2 (7.4%) >0.99∗∗
Seizure 3 (5.6%) 2 (7.4%) 1 (3.7%) >0.99∗∗
Weakness 5 (9.3%) 3 (11.1%) 2 (7.4%) >0.99∗∗
Fall down 2 (3.7%) 0 (0.0%) 2 (7.4%) 0.49∗∗
Pruritus 2 (3.7%) 0 (0.0%) 2 (7.4%) 0.49∗∗
†Student’s t-test. ‡Mann-Whitney U test. ∗Chi-Square test. ∗∗Fisher’s exact
test.
associated with administration of high doses of naloxone in
an intensive care unit (ICU) even for several days [16]. In spite
of all treatments performed, these patientsmay develop respi-
ratory arrest or death mainly because of the long-term effects
ofMTDor its latemanifestations. Some authors reported that
death was frequent in overdosed children and in adult after
intentional intoxication [17–19]. Although almost 80% of our
patients had intentionally consumed MTD, we had no death
report in our patients.
Although aspiration pneumonia (secondary to LOC),
acute lung injury, rhabdomyolysis, prolongation of QT inter-
val, torsade de pointes dysrhythmia, seizure (secondary to
hypoxia), and hypothermia have been mentioned as impor-
tant complications of MTD intoxication [9, 20–23], respi-
ratory failure is its most important fatal complication [24],
and bradypnea is the best predictor of respiratory depression
which responds to naloxone [25]. Once MTD-related respi-
ratory depression is suspected, initial management should
focus on airway support. Close attention should also be paid
to the patient’s ventilation. Bradypnea and pCO
2
elevation in
ABG are reliable signs of hypoventilation. Although pCO
2
increased in both groups, mean CO
2
increment was signif-
icantly higher in the placebo group.
Naloxone is the treatment of choice in opioid-related
respiratory depression [26]; however, higher initial doses
(2–10mg) and prolonged continuous IV infusions may be
needed to maintain adequate ventilation in cases with respi-
ratory arrest [27].
Many authors believe that delayed or recurrent respi-
ratory depression can be expected even after a dramatic
response to primary administration of naloxone because of
long elimination half-life ofMTD [28–30].Thus, they recom-
mend administration of a long-acting opioid antagonist like
NLTX to maintain adequate ventilation. Interestingly, all of
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Table 3: Patients clinical finding on arrival time (at ED).
Characteristics Total NLTX Placebo P value
𝑛 = 27 𝑛 = 27
Loss of Consciousness
Nil 28 (51.9%) 16 (59.3%) 12 (44.4%) 0.15‡
Grade I 17 (31.5%) 9 (33.3%) 8 (29.6%)
Grade II 6 (11.1%) 1 (3.7%) 5 (18.5%)
Grade III 1 (1.9%) 0 (0.0%) 1 (3.7%)
Grade IV 2 (3.7%) 1 (3.7%) 1 (3.7%)
Heart rate (Beat/min)
Mean ± SD 84 ± 14 85 ± 12 83 ± 17 0.71†
Systolic BP (mmHg)
Mean ± SD 114 ± 15 112 ± 13 117 ± 16 0.26†
Diastolic BP (mmHg)
Mean ± SD 74 ± 9 73 ± 8 74 ± 11 0.47†
Temperature (∘C)
Mean ± SD 37 ± 0.2 36.9 ± 0.3 37 ± 0.1 0.40†
Pupil size
Normal 12 (22.2%) 7 (25.9%) 5 (18.5%) 0.51∗∗
Miosis 42 (77.8%) 20 (74.1%) 22 (81.5%)
Mydriasis 1 (1.9%) 0 (0.0%) 1 (3.7%)
Dyspnea 21 (38.9%) 11 (40.7%) 10 (37.0%) 0.78∗
Cyanosis 13 (24.1%) 7 (25.9%) 6 (22.2%) >0.99∗
Bradypnea 25 (46.3%) 9 (33.3%) 10 (37%) 0.79∗
Tachypnea (RR > 32/min) 2 (3.7%) 0 (0.0%) 2 (7.4%) 0.49∗∗
Apnea occurrence 8 (14.8%) 3 (11.1%) 5 (18.5%) 0.70∗∗
Respiratory depression 21 (38.9%) 9 (33.3%) 12 (44.4%) 0.40∗
Taking naloxone 19 (35.2%) 9 (33.3%) 10 (37.0%) 0.78∗
Naloxone doses (mg)
Mean ± SD 1.4 ± 1.5 0.6 ± 0.4 2.2 ± 1.7 <0.01‡
ABG
pH
Mean ± SD 7.32 ± 0.08 7.34 ± 0.07 7.3 ± 0.09 0.05†
pCO2 (mmHg)
Mean ± SD 53 ± 10 50.6 ± 9 55.3 ± 10.6 0.09†
HCO3 (mmHg)
Mean ± SD 26.7 ± 4.2 27 ± 4.4 26.4 ± 4.1 0.61†
paO2 (mmHg)
Mean ± SD 48.4 ± 15.2 45.4 ± 16.1 51.6 ± 13.9 0.15†
O2 Saturation (%)
Mean ± SD 85 ± 7 89 ± 5 82 ± 7 0.13‡
†Student’s t-test. ‡Mann-Whitney U test. ED: emergency department, ABG: arterial blood gases.
∗Chi-Square test. ∗∗Fisher’s exact test.
the patients who received a single dose of 100mg NLTX had
a normal respiration during their hospitalization.
Tables 1 and 2 show that in prehospital setting no signif-
icant differences existed in the baseline characteristics of the
two groups. In prehospital stage, 11 patients (almost 20%) of
all participants experienced respiratory arrest, three of whom
had two episodes of apnea that had been reversed by naloxone
administration by paramedics. Respiratory failure was also
detected in nearly half of all patients on presentation or dur-
ing stay in ED.
Table 3 shows that received naloxone dose by case group
was less than that in the control group before NLTX admin-
istration. In fact, taking naloxone in 9 (33.3%) patients of the
NLTX group versus 10 (37%) in the placebo group revealed
that this difference was due to large doses of naloxone (more
than 4mg) for two ill cases in the placebo group. The signif-
icant difference in blood pH is also due to significant decrease
in pH of these two ill patients.
In this study, acute MTD complications significantly
occurred less in the patients who had received NLTX. Nearly
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Table 4: The laboratory data of the patients in both naltrexone and placebo groups.
Total NLTX Placebo P
Mean ± SD Median (range) Mean ± SD Median (range) Mean ± SD Median (range)
WBC ×106 𝜇L 11.5 ± 3.9 11.0 (34 to 21.7) 10.6 ± 34 10.1 (34 to 17) 12.3 ± 42 11.4 (65 to 2.17) 0.12†
RBC ×106 𝜇L 4.62 ± 0.48 4.56 (3.87 to 5.9) 4.68 ± 0.49 4.62 (3.87 to 5.52) 4.56 ± 0.49 4.51 (3.91 to 5.9) 0.40†
Hb (mg/dL) 13.1 ± 2.6 13.4 (1.3 to 16.6) 13.7 ± 1.9 14.1 (9.1 to 16.2) 12.5 ± 3.1 12.4 (1.3 to 16.6) 0.10†
Hct (%) 40.4 ± 4.6 39 (30.1 to 49.8) 40.8 ± 5 40.3 (30.1 to 48.4) 40 ± 4.3 39 (34 to 49.8) 0.64‡
Platelet ×103 𝜇L 225 ± 89 225 (46 to 599) 233 ± 100 232 (97 to 599) 217 ± 79 220 (46 to 396) 0.53†
Blood sugar (mg/dL) 117 ± 59 106 (50 to 317) 101 ± 41 91 (53 to 197) 133 ± 70 118 (50 to 317) 0.03‡
Blood urea (mg/dL) 27 ± 12 24 (15 to 69) 25 ± 8 24 (15 to 47) 29 ± 14 26 (15 to 69) 0.35‡
Creatinine (mg/dL) 1 ± 0.4 0.9 (0.6 to 3) 0.9 ± 0.2 0.9 (0.6 to 1.5) 1.1 ± 0.5 0.9 (0.6 to 3) 0.13‡
SGOT (U/L) 32 ± 37 22 (11 to 241) 22 ± 11 18 (12 to 63) 41 ± 49 25 (11 to 241) 0.04‡
SGPT (U/L) 28 ± 31 18 (5 to 167) 24 ± 22 16 (10 to 105) 32 ± 38 21 (5 to 167) 0.58‡
LDH (U/L) 519 ± 394 422 (216 to 2780) 526 ± 514 416 (290 to 2780) 514 ± 243 422 (216 to 1324) 0.26‡
CPK (U/L) 387 ± 914 110 (50 to 4450) 105 ± 37 99 (59 to 170) 656 ± 1231 144 (50 to 4450) 0.04†
ALP (U/L) 180 ± 61 175 (11 to 320) 177 ± 53 178 (98 to 310) 182 ± 69 172 (11 to 320) 0.80†
Na (mEq/L) 163 ± 169 139 (132 to 1346) 187 ± 241 139 (132 to 1346) 140 ± 3 140 (136 to 147) 0.73‡
K (mEq/L) 4 ± 0.4 4 (3.4 to 4.8) 4 ± 0.4 4 (3.4 to 4.6) 4.1 ± 0.4 4.1 (3.4 to 4.8) 0.17†
Bili. T (mg/dL) 0.6 ± 0.3 0.5 (0 to 1.4) 0.6 ± 0.3 0.5 (0 to 1.4) 0.6 ± 0.3 0.5 (0 to 1.4) 0.62‡
Bili. D (mg/dL) 0.2 ± 0.1 0.2 (0.1 to 1) 0.2 ± 0.2 0.2 (0.1 to 1) 0.2 ± 0.1 0.1 (0.1 to 0.3) 0.02‡
†Based on Student’s t-test. ‡Based on Mann-Whitney U test.
Table 5: Comparison of patients’ clinical status during hospitalization.
Outcome Total NLTX Placebo P value
𝑛 = 27 𝑛 = 27
Abnormality
Loss of consciousness 10 (18.5%) 0 (0.0%) 10 (37.0%) <0.01∗
Bradypnea 11 (20.4%) 0 (0.0%) 11 (40.7%) <0.01∗
Apnea 5 (9.3%) 0 (0.0%) 5 (18.5%) 0.02∗
ABG
Respiratory acidosis & hypercapnia 8 (14.8%) 1 (3.7%) 7 (25.9%) 0.05∗∗
Hypoxia 9 (16.7%) 1 (3.7%) 8 (29.6%) 0.02∗∗
Taking naloxone bolus 13 (24.1%) 1 (3.7%) 12 (44.4%) <0.01∗
Other clinical status
Naloxone iv Infusion 10 (18.5%) 0 (0.0%) 10 (37.0%) <0.01∗
Need for ICU care 14 (25.9%) 0 (0.0%) 14 (51.9%) <0.01∗
Hospital staying (hrs)
Mean ± SD 32 ± 20 26 ± 17 38 ± 21 0.009‡
Median (range) 24 (12 to 96) 20 (14 to 96) 32 (12 to 96)
∗Based on Chi-Square test. ∗∗Based on Fisher’s exact test. ‡Based on Mann-Whitney U test.
one third of the patients experienced respiratory depres-
sion during hospital stay. Interestingly, all of these patients
belonged to the placebo group that underwent standard treat-
ments. Theoretically, patients with acute long-acting toxicity
will need continuous infusion of naloxone for prevention of
recurrent apnea in spite of receiving enough initial doses of
naloxone. Also, these patients need close monitoring of the
vital signs preferably in the ICU. Lack of enough ICU beds,
pump infusion, and other monitoring systems as well as
agitation in a suicidal patient could be the main causes of not
receiving enough naloxone infusions and development of
sudden, life-threatening respiratory depression in them.This
study showed that NLTX could effectively prevent this com-
plication.
Also, 10% of all participants who were admitted to our
poison center re-experienced apnea and all of themwere from
the placebo group. Thus, this study shows that respiratory
depression was significantly less in the NLTX group.
Almost 40% of our patients in the placebo group experi-
enced LOC during hospitalization. Significant LOC can lead
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to aspiration pneumonia and prolonged hospitalization time
in these patients. No patient in NLTX group developed such
complication. Aspiration pneumonia andARDS happened in
two patients of the placebo group and none of the patients in
NLTX group.
Laboratory results were also different between the two
groups. Abnormal SGOT and CPK may reflect acute mus-
culoskeletal effects of MTD intoxication which led to rhab-
domyolysis in some patients, a condition previously demon-
strated in opioid overdose and defined as the most common
cause of poisoning-induced rhabdomyolysis in Iranian intox-
icated patients [4, 31]. Hyperglycemia was also more promi-
nent in placebo group and even high levels up to 319mg/dL,
supposed to be related to diabetes, were detected in these
patients. Ketotic or nonketotic hyperglycemic coma has
already been attributed to MTD overdose and its related
deaths [32, 33]. Therefore, high blood sugar may be an
indicator of severe toxicity, a sign thatwas controlled inNLTX
group. Further investigation is needed to confirm such
association.
Patients who received NLTX did not experience respira-
tory depression and LOC and did not need ICU care support
while those in the placebo group needed continuous admin-
istration of naloxone.On the other hand, 13 (24.1%) of total 54
patients needed antidote therapy with naloxone (bolus dose
associated with IV infusion for at least 10 hours), almost all
of whom were from the placebo group. Only one patient in
the NLTX group needed a single bolus dose of IV naloxone
(0.4mg) because of hypercapnia (pCO
2
> 45). However,
this patient had no sign and symptom of respiratory depres-
sion. The most important complication of MTD overdose is
respiratory arrest, especially in patients who do not receive
continuous IV naloxone. This research shows that apnea can
be prevented if opioid-naive patient takes NLTX. One of our
patients in group A showed acute withdrawal syndrome and
was excluded from the study although he had claimed to be a
nondependant to opioids.This accidentally precipitatedwith-
drawal syndrome suggests the use of naloxone before NLTX
administration when its safety is doubted even with the
patients who claim not to be dependent.
Hospital stay was significantly less in the NLTX group,
and this means that prescription of NLTX could prevent
important MTD-related complications such as aspiration
pneumonia secondary to LOC. It also seems that it is possible
to discharge asymptomatic patients with mild to moderate
MTD toxicity after prescribing a single 50mg dose of NLTX.
Although naloxone can lead to withdrawal syndrome or
acute lung injury in an opioid-dependent patient, it seems to
be safe in naive patients. Therefore, NLTX should be given
to those already awakened by naloxone because they are not
expected to develop a withdrawal syndrome.
Some authors believe that in most cases of intentional
MTD intoxication the patient should be observed at least for
48 hours [34]. After this time, he/she may be discharged once
respiration and mental status are normal and naloxone has
to be stopped for at least 6 hours before disposition. Current
study shows that these patients can be discharged sooner if
NLTX is administered to them. We, however, had to observe
our patients in NLTX group to be sure that unwanted
complications would not happen. None of our patients in the
NLTX group had bradypnea or respiratory arrest during hos-
pitalization.
Patients who ingest large amounts of MTD need to be
observed for at least 48 hours; they may need readminis-
tration of naloxone and must be under close monitoring of
respiration preferably in ICU. This study shows that admin-
istration of single dose of NLTX (50mg) can prevent respira-
tory compromise and patients can be safelymanaged in ward.
Opioid-naive patients with acute intentional MTD overdose
can be given a dose of NLTX without worrying about with-
drawal syndrome. Although we had no major complication
in our survey, theoretically, MTD half-life may be prolonged
in intoxicated patients exceeding theNLTXhalf-life.Thus, we
strongly recommend another re-enforcement dose of NLTX
at discharge time.
Our study supports the Nelson et al. hypothesis suggest-
ing that acute overdose with MTD and probably other long
acting 𝜇 opioid agonists can be effectively managed by NLTX
in opioid-naive patients [6].
5. Conclusion
Administration of oral NLTX is safe, well tolerated, and effec-
tive in preventing and treating respiratory depression/LOC-
related to acute MTD overdose in opioid-naive methadone-
intoxicated patients because there is not any risk for with-
drawal syndrome in them. A single dose of oral NLTX
can prevent recurrent or delayed life-threatening respiratory
depression in these patients. It also can significantly decrease
the length of hospital stay, need for ICU care, and costs of
treatment in methadone-naive intoxicated patients. It may
also be beneficial for treatment of other long-acting opioid
intoxications such as codeine, meperidine, and diphenoxy-
late. Further prospective investigations with more sample
sizes are warranted before the generalization of this approach
to other patient populations.
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